Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9819 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| AZD9819 | EXPERIMENTAL | Inhaled suspension |
| Placebo | PLACEBO_COMPARATOR | Inhaled suspension |
| Name | Type | Description |
|---|---|---|
| AZD9819 | DRUG | Inhaled single doses of suspension via SPIRA nebuliser |
| Placebo | DRUG | Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B) |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures * Healthy male and female (non-child bearing potential) subjects aged 18 to 50 years with suitable veins for cannulation or repeated venepuncture. * Have a body mass index (BMI) betw...
AZD9819 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial involving healthy volunteers, evaluating single and multiple ascending inhaled doses. The specific therapeutic indication for AZD9819 has not been disclosed.
AZD9819 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this investigational small molecule.
AZD9819 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA.
AZD9819 has been evaluated in one completed Phase 1 trial, NCT01166698, titled "Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects." The trial enrolled 100 healthy volunteers in the United Kingdom and assessed safety and tolerability.
The Phase 1 trial NCT01166698 was a single-center, double-blind, placebo-controlled study of single and multiple ascending inhaled doses of AZD9819 in healthy subjects. It enrolled 100 participants aged 18 years and older of all sexes in the United Kingdom.